Fund Description

The fund normally invests at least 80% of its assets in securities of companies that are principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes. This includes companies benefiting significantly from advancements in biotechnology, such as those involved in genetic analysis and engineering. The determination of whether a company is principally engaged in these activities can be based on its assets, income, sales, or profits, or a third-party industry classification. The fund primarily invests in common stocks of domestic and foreign issuers, utilizing fundamental analysis to select investments based on financial condition, industry position, and market conditions.